Incorporating User-Defined Hemodynamic Feedback in PBPK-PD Models
|
Jeff Kearns Preclinical pharmacokinetics and target occupancy of JDQ443, a covalent inhibitor targeting KRAS G12C
|
Andrew Stine A Multiscale Quantitative Systems Pharmacology Model of Pulmonary Arterial Hypertension
|
Tomoki Yoneyama A translational quantitative systems pharmacology modeling framework for exon skipping oligonucleotide therapies for Duchenne muscular dystrophy
|
Weize Huang A quantitative systems pharmacology (QSP) model to predict kinetics of TCR-engineered T cells in solid tumors
|
Quantitative Systems Pharmacology (QSP) Model Linking the Action of the CXCR4-Antagonist Mozobil to Both Immune Cell Mobilization from Bone Marrow and Immune Cell Infiltration in Colorectal Cancer (CRC)
|
Jessica Leete Virtual population simulations of an anti-PD-1 QSP model for first-in-human dose prediction
|
Jaehee Shim Predicting disease activity scores in Irritable Bowel Disease (IBD) by connecting simulated tissue biomarkers of a virtual population (VPop) to clinical biomarkers and outcomes using a novel algorithm
|
Integration of a potassium-aldosterone homeostasis model into a cardiorenal QSP model
|
Jin Niu Development of A Platform Quantitative Systems Pharmacology (QSP) Model to Predict the Clinical Responses of T-cell Redirecting Bispecific Antibodies in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
|
Kumpal Madrasi Prediction of a MABEL-based Starting Dose and Biologically Active Doses of a MSLN x CD137 bispecific conditional immune agonist(M9657) using a mechanistic QSP model
|
Tyler Cassidy QSP Modelling of MAPK Pathway in BRAF Mutant Melanoma Cells
|
Blerta Shtylla A novel virtual population simulation workflow for a QSP model of solid tumor targeted therapy
|
Gregory Ferl Mechanistic model for the impact of valency on cellular uptake and residualization of bispecific antibodies
|
Rolien Bosch Linking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity
|
Mechanistic Modeling of Heart Failure with Preserved Ejection Fraction: Understanding the Pathophysiology
|
Applying Population Mechanistic Modelling to Understand Population Level CAR-T Dynamics in Lymphoma Patients
|
Ted Rieger An Integrated QSP Model of Lipoproteins with Liver Metabolism for Non-Alcoholic Fatty Liver Disease and Hyperlipidemia
|
Hongtao Yu Mathematical modeling of the physiology of endothelin-1 and its receptors A and B
|
Ishaan Dave A semi-mechanistic model of the effect of renal function on BNP and NT-proBNP biomarkers
|
Tao Peng Development of a Quantitative Systems Pharmacology Model for Atopic Dermatitis: From Biological Pathways to Virtual Patients and Clinical Endpoints
|
Ronny Straube Effect of Breathing and Internalization on Antibody-Receptor Binding: What we can learn from the shape of the Binding Curve
|
Pharmacokinetics modeling and optimal dose prediction for a bispecific antibody against CD40 and PD1
|
Stepan Lerner The QSP model of microglia role in tau pathology and neurodegeneration
|
Denison Kuruvilla Predicting Anti-drug Antibody Incidence with a Quantitative Systems Pharmacology Immunogenicity Platform: A Case Study for Etrolizumab in Patients with Moderate to Severe Ulcerative Colitis
|
Oleg Demin Estimation of Imax and IC50 for PD1-PDL1 inhibition of T cell proliferation
|
Comparison of a typical PK/PD model versus a mechanistic QSP model to predict the Phase II of a PSCK9 inhibitor, using MonolixSuite
|
Oleg Demin Methodological aspects of rate law derivation of cell dynamics processes: focus on QSP model development
|
Tatiana Karelina Quantitative systems pharmacology modeling of immune response role in Parkinson’s disease
|
A quantitative systems pharmacology model for atopic dermatitis clinical trial design and biomarker identification: oral immunomodulator on top of topical steroids after induction period
|
Seshasai Pallikonda Chakravarthy Development of a mechanistic mPBPK/QSP Antibody drug conjugates (ADC) platform model with applications across preclinical, translational and clinical stages of drug development.
|
Clinical variance in CAR-T pharmacology deconvoluted using a mathematical model of T cell regulatory control
|
Aymara Sancho Araiz A mechanism-based pharmacokinetic/pharmacodynamic model for a novel oncolytic virus in monotherapy or combination with pembrolizumab.
|
Randolph Leiser A Quantitative Systems Pharmacology Model of Osteogenesis Imperfecta
|
Georgi Kapitanov Blinatumomab Trimer Formation - Insights From A Mechanistic PKPD Model On The Implications For Switching From Infusion To Subcutaneous Dosing Regimen In Acute Lymphoblastic Leukemia
|
Georgi Kapitanov Comparison Across Anti-PD-1 Antibodies - Insights From QSP-Based Meta-Analysis
|
Christina Battista Mathematical Modeling of Renal Sodium, Potassium, and Glucose Dynamics in Diabetic and Non-diabetic Simulated Populations
|
Chanchala Kaddi Quantitative Systems Pharmacology model of Achondroplasia connecting FGFR3 hyperactivity to growth velocity: case study with vosoritide
|
Vaibhav Maheshwari Mechanistic In Silico Assessment of PROTAC Mediated On- and Off-Target Degradation of Cellular Proteins
|
Zackary Kenz Representation of Fibrosis Stage within Mechanistic Model of Non-Alcoholic Fatty Liver Disease (NAFLD) / Non-Alcoholic Steatohepatitis (NASH) Aligns with Histologic Assessments
|
Polina Pchelintseva Quantitative systems pharmacology model for neurofilament L dynamics in multiple sclerosis and under immunomodulatory therapies.
|
Rohit Rao Quantitative Systems Pharmacology & Virtual Patients: A Novel Approach for Improved Generation of Plausible Patients using Farthest Point Optimization
|
Lara Clemens Proof-of-Concept that Variable Onset and Severity of T Cell-Mediated Drug-Induced Liver Injury is Reproduced in a Simulated Human Population
|
Mohammad Jafarnejad Quantitative Systems Pharmacology Modeling of Enzyme Replacement Therapies for Mucopolysaccharidosis Type II Reveals Key Brain & CSF PK/PD Relationships
|
The Impact of Tau Load and Genotypes on Cognitive Outcome in Amyloid Antibody Therapies. A Quantitative Systems Pharmacology Study
|
Christina Friedrich QSP Model of Aß Accumulation Predicts Different Treatment Effects at Different Stages of Alzheimer’s Disease
|
Rohit Rao A QSP model of COVID-19 facilitates the clinical development of nirmatrelvir, a novel oral anti-viral for the treatment of COVID-19
|
Parameters influencing target engagement of conditionally activated antibodies in tumor tissue: Investigations with a quantitative systems pharmacology model
|
Michael Reed Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology Model
|
Catherine Weathered Microglia Behavior in Alzheimer’s Disease: An Agent-Based Model to Elucidate Microglial Spatiotemporal Response to Amyloid Beta
|
Mechanistic target occupancy modeling for antibody format selection
|
Victor Sokolov An integrative mechanistic model of type 1 IFN-mediated inflammation in systemic lupus erythematosus
|